Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
214 hedge funds and large institutions have $3.27B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 78 increasing their positions, 71 reducing their positions, and 33 closing their positions.
127% more call options, than puts
Call options by funds: $129M | Put options by funds: $56.6M
10% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 71
0% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 33
2% less funds holding
Funds holding: 218 → 214 (-4)
28% less capital invested
Capital invested by funds: $4.57B → $3.27B (-$1.29B)
41% less funds holding in top 10
Funds holding in top 10: 17 → 10 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$121M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.9M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$40.7M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$21.9M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$82.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$63.6M |
| 3 |
Renaissance Technologies
New York
|
-$26.4M |
| 4 |
SPC
Slate Path Capital
New York
|
-$24.5M |
| 5 |
BlackRock
New York
|
-$23.3M |
RETA Hedge Fund Activity: Q1 2020 in Review
214 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2020, worth a combined $3.27B — down 28% from $4.57B a quarter earlier.
Fund positioning in RETA was balanced in Q1 2020: 33 funds opened new positions, 33 closed out, 78 added to existing stakes and 71 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $121M. The largest seller was T. Rowe Price Associates, cutting an estimated $82.3M.
- 214 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2020, down from 218 in Q4 2019.
- Funds reported $3.27B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2020, down 28% quarter-over-quarter.
- 33 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2020 and 33 closed out, a net change of 0 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2020 was Wellington Management Group, an estimated $121M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2020 was T. Rowe Price Associates, an estimated $82.3M sold.
Based on aggregated 13F filings for Q1 2020.